Cubist Systematic Strategies LLC trimmed its position in shares of PAREXEL International Co. (NASDAQ:PRXL) by 55.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,101 shares of the medical research company’s stock after selling 3,899 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in PAREXEL International were worth $270,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. World Asset Management Inc boosted its stake in PAREXEL International by 0.3% during the second quarter. World Asset Management Inc now owns 3,212 shares of the medical research company’s stock worth $279,000 after buying an additional 9 shares during the period. Amalgamated Bank boosted its stake in PAREXEL International by 0.6% during the second quarter. Amalgamated Bank now owns 7,259 shares of the medical research company’s stock worth $631,000 after buying an additional 42 shares during the period. Public Employees Retirement System of Ohio boosted its stake in PAREXEL International by 4.5% during the first quarter. Public Employees Retirement System of Ohio now owns 1,713 shares of the medical research company’s stock worth $108,000 after buying an additional 73 shares during the period. Texas Permanent School Fund boosted its stake in PAREXEL International by 0.5% during the second quarter. Texas Permanent School Fund now owns 37,062 shares of the medical research company’s stock worth $3,221,000 after buying an additional 169 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in PAREXEL International by 10.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,986 shares of the medical research company’s stock worth $173,000 after buying an additional 180 shares during the period. 87.45% of the stock is owned by institutional investors.

Shares of PAREXEL International Co. (NASDAQ:PRXL) opened at 88.08 on Tuesday. The stock has a market capitalization of $4.50 billion, a price-to-earnings ratio of 42.76 and a beta of 0.77. The company has a 50-day moving average of $87.85 and a 200-day moving average of $79.27. PAREXEL International Co. has a 1-year low of $51.16 and a 1-year high of $88.10.

PAREXEL International (NASDAQ:PRXL) last announced its earnings results on Monday, August 28th. The medical research company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.94 by $0.08. PAREXEL International had a return on equity of 19.95% and a net margin of 4.62%. The company had revenue of $557.20 million during the quarter, compared to analysts’ expectations of $537.59 million. During the same period last year, the business posted $0.94 EPS. On average, equities research analysts expect that PAREXEL International Co. will post $4.06 EPS for the current fiscal year.

Several research analysts have commented on PRXL shares. Zacks Investment Research raised shares of PAREXEL International from a “hold” rating to a “buy” rating and set a $98.00 price objective for the company in a research note on Thursday, August 31st. BidaskClub lowered shares of PAREXEL International from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 28th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the stock. PAREXEL International has an average rating of “Hold” and an average price target of $76.81.

COPYRIGHT VIOLATION WARNING: This news story was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark legislation. The correct version of this news story can be accessed at https://theolympiareport.com/2017/10/31/parexel-international-co-prxl-holdings-reduced-by-cubist-systematic-strategies-llc.html.

PAREXEL International Company Profile

PAREXEL International Corporation (PAREXEL) is a biopharmaceutical outsourcing services company. The Company provides a range of expertise in clinical research, clinical logistics, medical communications, consulting, commercialization, and technology products and services to pharmaceutical, biotechnology and medical device industries.

Want to see what other hedge funds are holding PRXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PAREXEL International Co. (NASDAQ:PRXL).

Institutional Ownership by Quarter for PAREXEL International (NASDAQ:PRXL)

Receive News & Ratings for PAREXEL International Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PAREXEL International Co. and related companies with Analyst Ratings Network's FREE daily email newsletter.